

DIVI'S LABORATORIES LIMITED

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2010

(Rs.in Lakhs)

		STAND ALONE			CONSOLIDATED		
	Particulars	Quarter ended 30.06.2010	Quarter ended 30.06.2009	Year Ended 31.03.2010	Quarter ended 30.06.2010	Quarter ended 30.06.2009	Year Ended 31.03.2010
		Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	Net Sales/Income from operations (Net of Excise Duty)	26254	20277	92928	26350	20583	94161
	Other Operating Income	276	942	1737	128	1167	2232
	<u>Total Income:</u>	26530	21219	94665	26478	21750	96393
2	<u>Expenditure:</u>						
	a. (Increase)/decrease in stock in trade and work in progress	(1424)	(2383)	(9924)	(1610)	(2050)	(9339)
	b. Consumption of Raw Material	11578	10577	39521	11608	10555	39658
	c. Purchase of Traded Goods	0	0	0	0	0	0
	d. Employees Cost	1737	1787	6846	1867	1918	7334
	e. Depreciation	1311	1286	5145	1312	1287	5148
	f. Other Expenditure						
	- Manufacturing Expenses	2124	1712	7174	2238	1719	7456
	- Other expenses	2231	1654	8126	2350	1773	8527
	g. Total	17557	14633	56888	17765	15202	58784
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	8973	6586	37777	8713	6548	37609
4	Other Income	490	285	1333	458	261	1202
5	Profit before Interest & Exceptional Items (3+4)	9463	6871	39110	9171	6809	38811
6	Finance charges	55	83	276	55	83	278
7	<u>Profit after Interest but before Exceptional items</u> (5-6)	9408	6788	38834	9116	6726	38533
8	Exceptional items	0	0	0	0	0	0
9	<u>Profit from ordinary activities before Tax</u> (7-8)	9408	6788	38834	9116	6726	38533
10	Tax Expense						
	- Current Tax	719	872	3120	719	872	3120
	- MAT Credit Entitlements	(5)	0	960	(5)	0	960
	- Deferred Tax	65	20	334	29	21	419
11	<u>Net Profit from ordinary activities after Tax:</u> (9-10)	8629	5896	34420	8373	5833	34034

12	Extra-ordinary items	0	0	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	8629	5896	34420	8373	5833	34034
14	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	2643	1297	2643	2643	1297	2643
15	Reserves excluding revaluation reserves as per balance sheet of previous accounting year			151565			149138
16	Earnings per Share:						
a)	Basic Earnings Per Share before extra-ordinary items Rs.	6.53	9.09	26.40	6.34	8.99	26.11
	Diluted Earnings Per Share before extra-ordinary items Rs.	6.52	9.01	26.35	6.32	8.91	26.06
b)	Basic Earnings Per Share after extra-ordinary items Rs.	6.53	9.09	26.40	6.34	8.99	26.11
	Diluted Earnings Per Share after extra-ordinary items Rs.	6.52	9.01	26.35	6.32	8.91	26.06
17	Public shareholding - No. of shares - Percentage of shareholding	62959045 47.64%	30263675 46.67%	62948545 47.64%	62959045 47.64%	30263675 46.67%	62948545 47.64%
18	Promoters and promoter group shareholding: a) pledged / encumbered b) non-encumbered: No. of shares Percentage of shares (as a % of the total shareholding of the promoter group) Percentage of shares (as a % of the total share capital of the company)	Nil 69185100 100% 52.36%	Nil 34584300 100% 53.33%	Nil 69195600 100% 52.36%	Nil 69185100 100% 52.36%	Nil 34584300 100% 53.33%	Nil 69195600 100% 52.36%

NOTES:

- The above results for the quarter ended 30th June 2010, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 12th August, 2010.
- The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
- The consolidated results include the unaudited results of the subsidiaries Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG.
- Figures for the previous year/period have been regrouped or recasted, wherever necessary.
- Exceptional item of Rs.5404 lakhs provided during the 1st quarter of last year towards tax liability of earlier years has been withdrawn as the relevant tax provisions have since been amended in Finance Act of 2010.
- The company is implementing a project for setting up a new Unit called "DSN SEZ Unit" at Visakhapatnam at an estimated cost of Rs.200 crores.
- Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 30.06.2010:
Opening: Nil, Received during the Quarter: 7, Resolved: 7, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 12th August, 2010

Dr. Murali K. Divi
Chairman & Managing Director